For more information and to register visit: https://cme.uchicago.edu/CARTCellSymposium19

Chimeric Antigen Receptor (CAR) T-Cell therapy represents a novel therapeutic approach which differs considerably from conventional management strategies.

It is critical that clinicians managing patients with acute leukemia and other hematologic malignancies are cognizant of relevant clinical updates and are also able to integrate recent progress into routine clinical management of these patients. However, given the overwhelming influx of data, many hematology professionals face difficulties in identifying the most relevant findings for clinical practice.

CAR T-Cell (“Living Drug”) immunotherapy is showing promising results in the treatment of cancers. University of Chicago faculty, along with national and international experts, will discuss the clinical and translational aspects of cell therapies both for hematologic malignancies and solid tumors.

Learning Objectives

• Identify the current indications for CAR T-cell therapy in cancer, including acute lymphoblastic leukemia and aggressive large B-cell lymphoma;
• State how to grade and manage CAR T-cell related toxicities including cytokine-release syndrome and neurologic toxicity;
• Identify novel targets and future directions in cellular therapy;
• Describe current approaches in nursing and supportive care for patients undergoing CAR T-cell therapy;
• Discuss how the uses of CAR T-cell therapy differ in pediatric and young adult patients

Target Audience

This activity is designed for medical oncologists and oncology fellows, basic scientists, research fellows, nurses, clinical trial research staff, immunologists, surgeons, and other healthcare professionals interested in tumor immunology and immunotherapy.

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.